Serina Therapeutics, Inc. · AMEX:SER
Serina Therapeutics — Investor Presentation (July 2025)
22 slides from Serina Therapeutics's investor presentation, Jul 29, 2025
Slide 1: POZ Platform: Next Generation Drug Product Optimization Platform
POZ Platform® June 2025 Non-Confidential • Next Generation Drug Product Optimization Platform Ticker (NYSE American): SER Shares outstanding: 10.0M Insider Ownership: 45% • Enabling Improvements of Multiple Drug Modalities
Slide 2: Forward Looking Statements
Forward Looking Statements NON-CONFIDENTIAL 2 This presentation contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “
Slide 3: POZ Platform across small molecules, RNA and ADCs
New / improved small molecule drugs in CNS indications Non-Confidential Small Molecules Optimized targeting & reduced immunogenicity of LNP-based RNA payloads RNA Improved targeting & delivery of cancer killing toxins ADCs • v1.0 license / collaboration with Pfizer in mRNA immunology • v2.0 / v3.0 i
Slide 4: POZylation: A Small Molecule Development Approach Designed to Reduce Risk
POZylation: A Small Molecule Development Approach Designed to Reduce Risk Only 10% of drugs that enter clinical development ultimately gain approval 40–50% of failures occur because the drug does not produce the intended therapeutic effect in humans, even if it showed promise in preclinical studies
Slide 5: How Does POZ Accomplish Continuous Drug Delivery of a Small Molecule?
Th erap eu tic W in d o w How Does POZ Accomplish Continuous Drug Delivery of a Small Molecule? • Drug is attached to multiple pendent groups via a cleavable linker • A single plasma enzyme (butyrylcholinesterase) releases the active drug POZ Time D ru g C o n ce n tr at io n Standard Drug Delivery
Slide 6: SER-252 (POZ-Apomorphine) for Advanced Parkinson's Disease
SER-252 (POZ-Apomorphine) Continuous Dopaminergic Stimulation (CDS) with Best-in-class Potential for Treatment of Advanced Parkinson’s Disease 10M people in the world are currently living with Parkinson’s disease Every 9 mins A person is diagnosed with Parkinson’s disease in the US alone 50+ years W
Slide 7: POZ Apomorphine: Optimizing product potential of clinically proven small molecule
NON-CONFIDENTIAL 7 • Apomorphine is a strong pan-receptor dopamine agonist • Similar to levodopa in terms of efficacy, but not dependent on the patient having intact presynaptic machinery to convert levodopa to dopamine and may be more appropriate than levodopa for advanced patients • Adoption of ap
Slide 8: POZ Apomorphine has Blockbuster Potential
POZ Apomorphine has Blockbuster Potential 1. Globe Life Sciences Primary Research NON-CONFIDENTIAL 8 • $2.1B to $3.3B Peak Sales Opportunity (US / EU / UK) Sa le s $ (M ) 0 500 1,000 1,500 2,000 2,500 3,000 3,500 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 US / EU / UK Total Sales 25% Pen
Slide 9: Patient Journey Inevitably Leads to Inadequate Control
Patient Journey Inevitably Leads to Inadequate Control NON-CONFIDENTIAL 9 Alternatives for advanced patients limited to highly invasive options Dyskinesia ON Time OFF Time High LowYEAR DRUG LEVEL 1 - 2 2 - 3 3 - 6 6+ Parkinson’s Diagnosis Impairment of Daily Functioning Development of Motor Complica
Slide 10: Major Market Opportunity for Advanced Parkinson's Therapies
Major Market Opportunity for Advanced Parkinson’s Therapies 1. Parkinson’s Foundation, accessed Mar 2024 2. Roche Pharma Day Epidemiological Data 2022 3. Various Analyst Reports from Oct 2019, Feb 2020, Dec 2023, Feb 2024 4. Based on Globe Life Sciences Primary Research NON-CONFIDENTIAL 10 US Advanc
Slide 11: SER-252 Potential Best-in-Class TPP
SER-252 Potential Best-in-Class TPP – 2x per week / 10 mins on- body LAI NON-CONFIDENTIAL 11 Duopa (Abbvie) levodopa / carbidopa Requires surgical placement of an intestinal port, patient wears a pump and 5 lb. gel pack during waking hours $471M in 2023 sales (75% ex-US) $511M peak sales in 2021 Dru
Slide 12: Apomorphine Causes Serious Administration Site Reactions
Apomorphine Causes Serious Administration Site Reactions NON-CONFIDENTIAL 12 Supernus’ ONAPGO (APO-go) TOLEDO Study: 31% of 82 Patients had Severe Local Site Issues • Apomorphine causes painful skin nodules in high number of patients • These nodules do not resolve – permanent painful scaring
Slide 13: POZ Apomorphine: No adverse skin reactions in NHPs
POZ Apomorphine: No adverse skin reactions in NHPs NON-CONFIDENTIAL 13 • POZ delivers free apomorphine specifically into the vascular circulation, avoiding release in the subcutaneous compartment. • The predictive translation from primate studies to humans is robust due to the identical enzyme respo
Slide 14: POZ Apomorphine is Partnered with Enable Injections
POZ Apomorphine is Partnered with Enable Injections 1. Approved in the United States in combination with a specific drug, for more information: https://enableinjections.com/our-products NON-CONFIDENTIAL 14 Approved 25mL enFuse device fully enables SER-252’s best-in-class product potential • Vial of
Slide 15: SER-252 Development Plan
2025 2026 2027 2028 2029 H1 H2 H1 H2 H1 H2 H1 H2 H1 SER-252 Development Plan 15 IND Studies Pre-IND Meeting Phase 2b/3 in Advanced PD PatientsPhase 1b in Advanced PD Patients Interim Data Final Data • Design: Single Ascending Dose / Multiple Ascending Dose • Primary Endpoint: o Safety and tolerabili
Slide 16: SER-270 (POZ-VMAT2 inhibitor)
SER-270 (POZ-VMAT2 inhibitor) VMAT2 inhibitor-based long-acting injectable (LAI) in movement disorders Tardive Dyskinesia & Huntington’s Chorea 800K people in the US are currently living with Tardive dyskinesia Only 50K patients are currently being treated with VMAT2 inhibitors VMAT2i’s are the only
Slide 17: SER-270 / POZ-VMAT2i for Tardive Dyskinesia
SER-270 / POZ-VMAT2i for Tardive Dyskinesia (TD) VMAT2 inhibitor-based LAI product candidate optimized for one week PK profile in movement disorders Tardive Dyskinesia & Huntington’s Chorea • TPP: Long acting injectable vs. twice daily orals • PK Profile: near zero-order, providing constant drug lev
Slide 18: US Market Metrics: LAI Target Segments
US Market Metrics $3.7B LAI Target Segments • Primary Indication: Tardive Dyskinesia: POZ-VMAT2i targets a large and growing market with significant unmet needs, focusing on non-compliant psychiatric patients and those facing swallowing difficulties. • Secondary Indication: Chorea/Huntington’s Disea
Slide 19: Overview of VMAT2i Class
Overview of VMAT2i Class – 2024 US sales of $3.7 billion • Analysts forecast 2030 US Sales of $5.4B as only approved drug class for TD Confidential *Tetrabenazine was first approved for the treatment of chorea in movement disorders in the UK in1971, then received wider European approval by 2000 **Ba
Slide 20: Team Momentum
Team Momentum Senior Leadership / Board of Directors has been completely transformed in past year. have led early investments and/or built companies as C-suite leaders having achieved total exit value of approximately $50 billion. Leadership Transformation Key Investors & Board Members
Slide 21: Strategic Support & High Insider Ownership
Strategic Support & High Insider Ownership The drug development & investment platform company of biotech investor Greg Bailey. Record of leading 2 of the 10 largest biopharma exits in the last decade: Biohaven (Pfizer) for $11 billion, Medivation (Pfizer) for $14 billion. Juvenescence is Serina’s la
Slide 22: Significant Milestones
Significant Milestones NON-CONFIDENTIAL 22 Product Development / Data • Aug 2025 – FDA allowance for Phase 1b trial of SER-252 in Advanced Parkinson’s • Aug 2025 – 505(b)(2) NDA regulatory pathway visibility • Sep 2025 – IND submission with FDA • Nov 2025 – Initiation of Phase 1b trial of SER-252 in
Serina Therapeutics — Investor Presentation (July 2025) on 6ix